Inhibition of mTOR Signaling Reduces PELP1-Mediated Tumor Growth and Therapy Resistance
- 1 June 2014
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 13 (6) , 1578-1588
Abstract
Proline, Glutamic acid-, and Leucine-rich Protein 1 (PELP1) is a proto-oncogene that modulates estrogen receptor (ER) signaling. PELP1 expression is upregulated in breast cancer, contributes to therapy resistance, and is a prognostic marker of poor survival. In a subset of breast tumors, PELP1 is predominantly localized in the cytoplasm and PELP1 participates in extranuclear signaling by facilitating ER interactions with Src and phosphoinositide 3-kinase (PI3K). However, the mechanism by which PELP1 extranuclear actions contributes to cancer progression and therapy resistance remains unclear. In this study, we discovered that PELP1 cross-talked with the serine/threonine protein kinase mTOR and modulated mTOR signaling. PELP1 knockdown significantly reduced the activation of mTOR downstream signaling components. Conversely, PELP1 overexpression excessively activated mTOR signaling components. We detected the presence of the mTOR signaling complex proteins in PELP1 immunoprecipitates. mTOR-targeting drugs (rapamycin and AZD8055) significantly reduced proliferation of PELP1-overexpressed breast cancer cells in both in vitro and in vivo xenograft tumor models. MCF7 cells that uniquely retain PELP1 in the cytoplasm showed resistance to hormonal therapy and mTOR inhibitors sensitized PELP1cyto cells to hormonal therapy in xenograft assays. Notably, immunohistochemical studies using xenograft tumors derived from PELP1 overexpression model cells showed increased mTOR signaling and inhibition of mTOR rendered PELP1-driven tumors to be highly sensitive to therapeutic inhibition. Collectively, our data identified the PELP1–mTOR axis as a novel component of PELP1 oncogenic functions and suggest that mTOR inhibitor(s) will be effective chemotherapeutic agents for downregulating PELP1 oncogenic functions. Mol Cancer Ther; 13(6); 1578–88. ©2014 AACR.Keywords
All Related Versions
This publication has 46 references indexed in Scilit:
- LAS1L interacts with the mammalian Rix1 complex to regulate ribosome biogenesisMolecular Biology of the Cell, 2012
- The SUMO system controls nucleolar partitioning of a novel mammalian ribosome biogenesis complexThe EMBO Journal, 2011
- Significance of ER–Src axis in hormonal therapy resistanceBreast Cancer Research and Treatment, 2010
- Cyclin-Dependent Kinase–Mediated Phosphorylation Plays a Critical Role in the Oncogenic Functions of PELP1Cancer Research, 2010
- PELP1: A novel therapeutic target for hormonal cancersIUBMB Life, 2010
- Nuclear Receptor Coregulators in Cancer BiologyCancer Research, 2009
- The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase CThe EMBO Journal, 2008
- Oncogenic Potential of the Nuclear Receptor Coregulator Proline-, Glutamic Acid–, Leucine-Rich Protein 1/Modulator of the Nongenomic Actions of the Estrogen ReceptorCancer Research, 2007
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002